文献速递临床试验与 GCP

儿童青少年神经性厌食症及其家庭的家庭治疗(HoT研究):随机对照多中心开放标签平行组优效性试验的研究方案

Anorexia nervosa-specific home treatment in children and adolescents and their families (the HoT study): a study protocol of a randomized, controlled, multicenter, open-label, parallel group superiority trial.
PubMed 文献 · Trials · 2024-11-13

该研究为多中心随机对照开放标签平行组优效性试验,在德国5家主要治疗中心开展,纳入约240例12至18岁因神经性厌食症住院的患者,经5至8周住院躯体稳定后随机分入常规治疗组或家庭治疗组(每组82例,共164例),主要结局为入组12个月后的BMI,并评估进食障碍精神病理、再住院、生活质量、照护者负担及直接治疗成本等。

要点

  • 研究旨在比较家庭治疗与常规住院或日间治疗对儿童青少年神经性厌食症的疗效与安全性。
  • 主要结局为入组12个月后的BMI,校正病前BMI和入院BMI。
  • 次要结局包括精神病理、再住院次数与时长、生活质量、治疗动机与满意度、照护者负担及直接治疗成本。

核心结论

  • 若评估结果为阳性,家庭治疗可被视为替代或补充住院治疗等既定方法的有效治疗手段。
  • 家庭治疗环境可能缩短该患者群体的住院时间、提高治疗满意度并有助于降低再住院风险,而再住院风险降低与该脆弱患者群体的更好结局相关。

研究设计与样本

  • 多中心随机对照开放标签平行组优效性试验,在德国5家主要神经性厌食症治疗中心开展。
  • 纳入约240例因神经性厌食症住院的12至18岁儿童青少年,经5至8周住院躯体稳定期后随机分入常规治疗组或家庭治疗组(每组82例,共164例)。
  • 在入组、随机化和出院时进行三次评估,并在入组后9个月和12个月进行随访评估。
  • 统计分析基于意向性治疗原则,采用重复测量混合模型。

主要发现

  • 主要结局为入组12个月后的BMI,组间比较校正病前BMI和入院BMI。
  • 次要结局包括进食障碍和一般精神病理、精神科再住院次数和时长、生活质量、治疗动机和治疗满意度。
  • 其他次要结局包括主要照护者的负担和处理患儿疾病的能力以及直接治疗成本。
  • 整个治疗期间评估(严重)不良事件;此外评估家庭治疗的可行性和实施情况以及两组多学科治疗团队成员的满意度和工作量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New treatment approaches are urgently needed to improve the prognosis of children and adolescents with anorexia nervosa (AN). Recently, the feasibility of multidisciplinary home treatment that strongly involves the patients' parents/caregivers has been investigated. However, no RCT has yet been performed to test the efficacy and safety of this approach compared to standard treatment approaches, such as inpatient treatment. METHODS: In this multicenter randomized-controlled trial, home treatment for children and adolescents with AN aged 12 to 18 years is established at 5 major treatment centers for AN in Germany. Approximately 240 patients who are admitted to the hospital for AN will be included in the trial. After a short inpatient somatic stabilization phase (5-8 weeks), patients are randomized to receive either treatment as usual (TAU), in the form of continued inpatient or day patient treatment, or the newly developed home treatment (HoT) (n = 82/arm, n = 164 in total). There are three assessments throughout treatment (admission, randomization, and discharge), as well as follow-up assessments at 9 and 12 months after admission. The BMI at 12 months after admission (primary outcome) is compared between groups (adjusted for premorbid BMI and admission BMI); secondary outcomes include eating disorder and general psychopathology, the number and duration of psychiatric rehospitalizations, quality of life, motivation for treatment and treatment satisfaction. Other secondary outcomes include the primary caregivers' burden and skills in handling the child's illness and direct treatment costs. Statistical analysis will be based on intention-to-treat principles, using mixed models for repeated measures. (Serious) adverse events are assessed throughout treatment. In addition, the feasibility and implementation of HoT as well as the satisfaction and workload of the members of the multidisciplinary treatment teams in both arms will be assessed. DISCUSSION: In the case of a positive evaluation, HoT can be considered an effective treatment method to replace or complete established treatment methods, such as IP, for treating AN in children and adolescents. The home treatment setting might shorten inpatient stays in this patient group, increase treatment satisfaction, and help to reduce the risk of rehospitalization, which is associated with a better outcome in this vulnerable patient group. TRIAL REGISTRATION: The trial was registered with the German Clinical Trial Register (DRKS) under the ID DRKS00025925 on November 26, 2021 (prospectively registered): https://drks.de/search/de/trial/DRKS00025925 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dahmen B, Zielinski-Gussen I, Föcker M, et al. Anorexia nervosa-specific home treatment in children and adolescents and their families (the HoT study): a study protocol of a randomized, controlled, multicenter, open-label, parallel group superiority trial. Trials. 2024. PMID: 39538317. doi:10.1186/s13063-024-08566-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。